Description
Oglemilast(GRC3886) is a potent inhibitor of PDE4.
Product Overview
Among the emerging agents to treat COPD or asthma, phosphodiesterase 4 (PDE4) inhibitors have attracted particular attention. PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications. Oglemilast is an orally administered inhibitor drug which is touted as an important and novel therapeutic target for asthma and chronic obstructive pulmonary disease (COPD), also known as smokers cough. Clinical trial: Glenmark Pharmaceuticals'licensing partner, Forest Laboratories, announced that the Phase IIb results on Oglemilast did not show a statistically meaningful increase from the baseline compared to the placebo (dummy drug). The markets took to this badly and the stock was pummeled on the bourses.
Synonyms
GRC 3886; GRC-3886; GRC3886
IC50
2.5 nM (PDE4B) and 1.7 nM (PDE4D)
Molecular Formula
C20H13Cl2F2N3O5S
Chemical Name
N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
Solubility
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
In vitro
Oglemilast (GRC-3886), a potent PDE4 inhibitor, inhibited PDE4 enzyme with an IC50 value of 1.4 nM and exhibited >7,000-fold selectivity over other PDE (PDE1-11) families. In human whole blood assays, oglemilast inhibited LPS-induced TNFα production with an IC50 value of 190 nM and.
In vivo
Oglemilast oral treatment of rats blocked Lipopolysaccharide (LPS)-induced pulmonary neu-trophilia with an ID50 of 1.45 mg/kg. In ferrets, oglemilast neither induced emesis nor caused any behavioral changes associated with emesis at 100 mg/kg. Hence, oglemilast could represent a new generation of potent selective PDE4 inhibitor with significantly improved emetic side-effect profile.
Download Datasheet